Teltow/Berlin, 19.07.2016 - This year's shareholders' meeting of co.don AG (ISIN DE000A1K0227) was held in Berlin on 14 July 2016. The shareholders attending, who represented 46.5% of the 16.2 million voting shares, approved all the proposals put forward by company management.
Dirk Hessel, CEO of co.don AG, reported on the financial year 2015 and the course of business in the first half of 2016. "2015 was an important year for co.don AG. For one thing it was the most successful year in the company's history to date, and for another, 2015 was the year the transformation of co.don AG began. A biotech company focused on research and development is now becoming a fully integrated, biopharmaceuticals company and part of the Mittelstand. In 2015 the company increased its revenues year on year by 13.6%", said Hessel. "The financial year 2016 also started well for co.don, with rapid revenue growth of 23% in the first quarter compared with the same period a year ago. The ongoing success of the company's restructuring and its preparations for EU market entry mean the company is well on track. The portfolio and market presence of Bauerfeind AG, our new anchor shareholder, also open up new opportunities for the company's international expansion and commercialisation."
The members of the Executive Board and Supervisory Board were exonerated for the financial year 2015. Roever Broenner Susat Mazars GmbH & Co. KG Wirtschaftsprüfungs- und Steuerberatungsgesellschaft, Hamburg, was appointed as auditor for 2016. New Supervisory Board elections were required, since the terms of office of Prof. Dr Barbara Sickmüller and Dr Bernd Wegener ended at the close of the shareholders' meeting on 14 July 2016. Dr Bernd Wegener and Prof. Dr Barbara Sickmüller were re-elected to the Supervisory Board. Mr Pettersen and Mr Talyanskiy resigned their Supervisory Board seats as of 15 August 2016. Shareholders approved the proposal by the former major shareholder OSEMIFARO to elect Professor Hans Bauerfeind and Ms Beatrix Bauerfeind-Johnson to the Supervisory Board with effect from 16 August 2016.
About co.don® AG: Berlin-based co.don AG develops, produces and markets in Germany autologous cell therapies for the minimally invasive repair of cartilage damage to joints following traumatic or degenerative defects. co.don condrosphere® is a cell therapy product that uses only the patient's own cartilage cells ("autologous chondrocytes"). co.don condrosphere® has been approved by the German federal agency PEI in accordance with Section 4b of the German Pharmaceuticals Act (AMG) and is currently undergoing Phase II and III clinical trials to obtain European marketing authorisation. co.don condrosphere® has been used for more than 10 years in over 120 clinics to treat more than 10,000 patients. In Germany the statutory health insurance companies have paid for the treatment of knee and hip joints since 2007 and for the treatment of vertebral joints since 2008. The shares in co.don AG are listed on the Frankfurt Stock Exchange (ISIN: DE000A1K0227). Executive Board: Dirk Hessel (CEO), Ralf M. Jakobs (CFO), Vilma Methner (COO, CSO). More information is available at www.ihre-zellzuechter.de or www.codon.de
Tel. +49 (0)3328-43460
Fax +49 (0)3328-434643